Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma-Reference-Cited by-同舟云学术

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Published:2013-01 Issue:1 Volume:19 Page:123-128
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Vose Julie M.,Bierman Philip J.,Loberiza Fausto R.,Enke Charles,Hankins Jordan,Bociek Robert G.,Chan Wing C.,Weisenburger Dennis D.,Armitage James O.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference36 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma;Coiffier;N Engl J Med,2002

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

3. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005

4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

5. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma;Moskowitz;J Clin Oncol,1999

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Transplantation;Clinical Immunology;2023

3. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma;Blood Advances;2021-12-08

4. Nanobodies in cancer;Seminars in Immunology;2021-02

5. Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma;Clinical Cancer Research;2019-09-03